Browse the evidence

81.5% of patients achieved excess weight loss (EWL) ≥50% and 51.1% achieved EWL ≥70% during follow-up.

Surgeons can expect a significant proportion of patients to achieve substantial weight loss post-surgery.

Laparoscopic Roux-en-Y gastric bypass (LRYGB) results in higher rates of sustained excess weight loss compared to laparoscopic sleeve gastrectomy (LSG).

LRYGB may be a more effective option for patients seeking long-term weight loss.

A greater proportion of AOM-naïve patients achieved ≥15% and ≥20% total body weight loss at 12 months compared to non-AOM-naïve patients.

Clinicians should note that AOM-naïve patients are more likely to achieve significant weight loss with semaglutide.

Semaglutide improved hemoglobin A1c levels and reduced glycemic variability without increasing hypoglycemia.

Semaglutide may enhance glycemic control in type 1 diabetes patients.

Several agencies have approved tirzepatide for the treatment of type 2 diabetes and obesity.

Tirzepatide is a viable treatment option that is recognized by regulatory agencies for managing type 2 diabetes and obesity.

Tirzepatide has potential cardiovascular benefits.

Practitioners should consider the cardiovascular implications when prescribing TZP.

Brown adipose tissue (BAT) is identified as a thermogenic organ in human adults, which may be targeted for obesity and cardiometabolic disease treatment.

Activating BAT could be a novel strategy for treating obesity and related diseases.

Integrating shared decision-making (SDM) into obesity management enhances patient-centered care and has the potential to improve long-term outcomes.

Practitioners should consider incorporating SDM to enhance patient engagement and outcomes in obesity care.

Programs incorporating SDM reported improved patient engagement, satisfaction, and health outcomes across diverse demographic groups.

Incorporating SDM can lead to better patient experiences and outcomes in obesity management.

Common facilitators of SDM success include the use of decision aids, culturally tailored counseling, and multidisciplinary team involvement.

Healthcare providers should utilize decision aids and culturally tailored approaches to enhance SDM in obesity care.

Long-term intake of UPFs leads to addiction due to additives including fat, caffeine, and sugar.

Health professionals should consider the addictive potential of UPFs when advising clients.

Significant improvements were observed across quality-of-life scores.

Incorporating exercise and nutrition can enhance the quality of life for breast cancer patients.

Delaying breakfast from 0700 h to 0930 h or 1200 h reduces postprandial glycaemia.

Practitioners can recommend delaying breakfast to improve glycaemic control in patients with type 2 diabetes.

Associations between obesity and health are likely causal.

Understanding that obesity has likely causal links to health can guide interventions.

Incretin mimetics have a positive impact on related comorbidities, such as sleep apnea and heart failure.

Practitioners should be aware of the broader health benefits of incretin mimetics beyond glucose control.

Patients may benefit from education on proper drug administration, anticipated adverse effects, and nutrition considerations with treatment.

Educating patients on these aspects can improve treatment adherence and outcomes.

Durable LVAD patients treated with GLP-1 RA had a significant weight reduction from 116 kg to 110 kg (p-value < 0.001).

GLP-1 RA may be effective for weight management in LVAD patients.

GLP-1 RA therapy improved HBA1C levels from 6.4 to 5.7 (p-value 0.003) in LVAD patients.

GLP-1 RA may help improve glycemic control in LVAD patients.

White rice intake is associated with a 18% increased risk of type 2 diabetes mellitus (T2DM) when comparing the highest with the lowest category of intake.

Practitioners should consider the potential increased risk of T2DM when advising on white rice consumption.

Every additional 150 grams of white rice intake per day is associated with a 6% greater risk of T2DM.

Increasing white rice intake may elevate T2DM risk, which should be considered in dietary recommendations.

Dulaglutide showed consistent reductions in HbA1c (1.1%) and weight (1.2 kg).

Dulaglutide is an effective alternative for glycemic control and weight management in T2DM patients.

Several emerging oral agents have demonstrated promising efficacy, achieving weight loss of ≥10% in clinical trials.

Practitioners may consider these oral agents as effective options for weight management.

Incretin-based anti-obesity medications are gaining interest for their potential role in preconception care.

Healthcare providers should consider the use of incretin-based medications in preconception counseling.

Ninety-day medical complications were significantly reduced in GLP-1 RA users across BMI categories ≥25.

Practitioners may consider GLP-1 RA use to reduce post-operative complications in obese patients.